US Stock MarketDetailed Quotes

MRSN Mersana Therapeutics

Watchlist
  • 0.582
  • -0.027-4.48%
Close Feb 14 16:00 ET
  • 0.589
  • +0.007+1.20%
Post 20:01 ET
71.90MMarket Cap-0.97P/E (TTM)

About Mersana Therapeutics Company

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Company Profile

SymbolMRSN
Company NameMersana Therapeutics
Listing DateJun 28, 2017
Issue Price15.00
Founded2001
CEODr. Martin H. Huber, M.D.
MarketNASDAQ
Employees123
Fiscal Year Ends12-31
Address840 Memorial Drive
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-617-498-0020

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Martin H. Huber, M.D.
  • Director, President and Chief Executive Officer
  • 2.60M
  • Mohan Bala
  • Senior Vice President and Chief Development Officer
  • 1.58M
  • Dr. Timothy B. Lowinger, PhD
  • Senior Vice President, Chief Science and Technology Officer
  • 1.69M
  • Alejandra Carvajal
  • Senior Vice President and Chief Legal Officer
  • 1.61M
  • Brian DeSchuytner
  • Senior Vice President, Chief Operating Officer and Chief Financial Officer
  • 1.74M
  • Dr. Tushar Misra, PhD
  • Senior Vice President and Chief Manufacturing Officer
  • --
  • Ashish Mandelia
  • Vice President, Controller and Principal Accounting Officer
  • --
  • David M. Mott
  • Chairman of the Board
  • 329.93K
  • Anna Protopapas
  • Director
  • 4.45M
  • Lawrence M. Alleva
  • Independent Director
  • 308.93K
  • Dr. Willard H. Dere, M.D.
  • Independent Director
  • 305.43K
  • Dr. Kristen M. Hege, M.D.
  • Independent Director
  • 293.43K
  • Dr. Andrew A. F. Hack, M.D.,PhD
  • Independent Director
  • 297.43K
  • Allene M. Diaz
  • Independent Director
  • 294.93K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More